Implant allergy and total knee arthroplasty. What is the first-line management? Therapeutic options and outcomes
Background: Total knee arthroplasty (TKA) is a frequent procedure, yet persistent postoperative pain remains a significant cause for revision. Metal hypersensitivity, a type IV delayed immune reaction mediated by T-lymphocytes, is a controversial etiologic factor implicated in approximately 0.6% to 1% of TKA revisions.
Objective: This article reviews the pathophysiological mechanisms of implant-related allergy, evaluates current diagnostic modalities, and analyzes clinical outcomes of hypoallergenic prosthetic alternatives in primary and revision settings.
Key Points: Metal sensitization prevalence is estimated at 10% to 15% in the general population, increasing to 60% in cases of implant failure. Common haptens include nickel, cobalt, and chromium. Diagnosis relies on cutaneous patch testing and the lymphocyte transformation test (LTT), though both exhibit limitations in specificity and clinical correlation. Management of confirmed allergy involves hypoallergenic implants utilizing titanium nitride (TiN), zirconium nitride (ZrN), or ceramicized components like Oxinium. Prospective studies indicate that functional outcomes and ten-year survival rates for hypoallergenic implants in primary TKA are comparable to standard cobalt-chromium prostheses. However, registry data from the United Kingdom and Australia demonstrate higher cumulative revision rates for hypoallergenic designs, particularly in younger patient cohorts. In revision surgery for suspected allergy, outcomes are heterogeneous, with some series showing improved range of motion and pain relief following the use of coated implants.
Conclusion: While hypoallergenic prostheses are viable for patients with confirmed symptomatic metal allergy, their routine use is not supported by registry data showing inferior long-term survivorship compared to standard implants. Diagnosis requires systematic exclusion of infection and mechanical loosening.
